News
Public · Published
Tarsus Pharmaceuticals (TARS) Reports XDEMVY Sales of $194.6M, Up Approximately 64%
Tarsus Pharmaceuticals reported third-quarter 2026 XDEMVY net product sales of $194.6M, up about 64% from a year earlier. Cumulative sales since launch passed $1B, over 1 million bottles were dispensed, and Neera Clase was appointed Chief Commercial Officer.
Published:
Updated:
What happened
Tarsus Pharmaceuticals reported third-quarter 2026 XDEMVY net product sales of $194.6M, up about 64% from a year earlier. Cumulative sales since launch passed $1B, over 1 million bottles were dispensed, and Neera Clase was appointed Chief Commercial Officer.
Confirmed
Global impact / market context
XDEMVY is Tarsus's approved commercial product, so its sales growth is the main signal of how well the company turns prescriptions into revenue. Rising sales can fund research and operating costs, while slower growth would put more pressure on spending plans.
Analyst inference
The update gives sales and dispensing milestones but no prior-year dollar figure, profit per sale, or pipeline news. Investors weighing Tarsus therefore have limited detail on costs and cash available, and the commercial leadership change adds execution uncertainty.
Analyst inference
What to watch
- Future quarterly XDEMVY sales reports will show whether the roughly 64% growth rate continues after this quarter's $194.6M result. Confirmed
- Watch for company disclosure on Neera Clase's priorities as Chief Commercial Officer, since the release gave no details on her plans. Proposed
- Track pipeline updates beyond XDEMVY, because reliance on one product ties Tarsus's revenue and capital spending capacity to that product's demand. Analyst inference